CASI Pharmaceuticals Announces Termination of Global Chief Medical Officer Dr. Alexander A. Zukiwski

On April 20, 2026, CASI Pharmaceuticals, Inc. announced a change to its executive management team as part of an ongoing effort to streamline its U.S. operations. Dr. Alexander A. Zukiwski, MD, the Company’s Global Chief Medical Officer, has entered into an agreement regarding the termination of his role without cause, effective immediately. CASI Pharmaceuticals, a clinical-stage biopharmaceutical company focused on developing CID-103 (an anti-CD38 monoclonal antibody) for organ transplant rejection and autoimmune diseases, is currently searching for a suitable successor for the Global Chief Medical Officer position. In the interim, Dr. Zukiwski’s responsibilities have been assumed by other members of the current management team, primarily Dr. Junping Chen, MD, PhD, who serves as the Company’s China Chief Medical Officer. The company stated this transition aligns with its long-term business plan and strategic restructuring of its branches and personnel in the United States.